Mucosal 5-aminosalicylic acid concentration inversely correlates with severity of colonic inflammation in patients with ulcerative colitis. - Wikidata - wikimedia - TriplyDB

Mucosal 5-aminosalicylic acid concentration inversely correlates with severity of colonic inflammation in patients with ulcerative colitis.

Mucosal 5-aminosalicylic acid concentration inversely correlates with severity of colonic inflammation in patients with ulcerative colitis.

http://www.wikidata.org/entity/Q35361187

about

Medical Therapy of Active Ulcerative Colitis Ultrasound-mediated gastrointestinal drug delivery.Review article: maintenance therapy in patients with ulcerative colitis Comparison of efficacy of multimatrix mesalazine 4.8 g/day once-daily with other high-dose mesalazine in active ulcerative colitis: a randomized, double-blind study Indications for 5-aminosalicylate in inflammatory bowel disease: is the body of evidence complete?European evidence-based Consensus on the management of ulcerative colitis: Current management.Therapeutic efficacy of pH-dependent release formulation of mesalazine on active ulcerative colitis resistant to time-dependent release formulation: analysis of fecal calprotectin concentration The immunologic effects of mesalamine in treated HIV-infected individuals with incomplete CD4+ T cell recovery: a randomized crossover trial Efficacy and safety of mesalamine suppositories for treatment of ulcerative proctitis in children and adolescents.Novel drug delivery strategies for the treatment of inflammatory bowel disease.Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-gamma Review article: evolutionary advances in the delivery of aminosalicylates for the treatment of ulcerative colitis.Review article: mode of action and delivery of 5-aminosalicylic acid - new evidence.5-ASA colonic mucosal concentrations resulting from different pharmaceutical formulations in ulcerative colitis.Usefulness of sulfasalazine for patients with refractory-ulcerative colits.Effectiveness of a hydroxynaphthoquinone fraction from Arnebia euchroma in rats with experimental colitis Review article: delivery and efficacy of topical 5-aminosalicylic acid (mesalazine) therapy in the treatment of ulcerative colitis.Multiparticulate systems containing 5-aminosalicylic acid for the treatment of inflammatory bowel disease.New targeting strategies in drug therapy of inflammatory bowel disease: mechanistic approaches and opportunities.Nanotechnology in the treatment of inflammatory bowel diseases.Once-daily MMX mesalamine for the treatment of mild-to-moderate ulcerative colitis.Review article: The pharmacokinetics and pharmacodynamics of drugs used in inflammatory bowel disease treatment.The long journey of salicylates in ulcerative colitis: The past and the future.Regulatory framework on bioequivalence criteria for locally acting gastrointestinal drugs: the case for oral modified release mesalamine formulations.Low-frequency ultrasound for drug delivery in the gastrointestinal tract.Bioavailability and therapeutic activity of alicaforsen (ISIS 2302) administered as a rectal retention enema to subjects with active ulcerative colitis.A dynamic model of once-daily 5-aminosalicylic acid predicts clinical efficacy.Measurement of colonic mucosal concentrations of 5-aminosalicylic acid is useful for estimating its therapeutic efficacy in distal ulcerative colitis: comparison of orally administered mesalamine and sulfasalazine.Simulated comparison of topical and oral formulations of 5-aminosalicylate for the treatment of ulcerative colitis.Mesalazine (5-aminosalicylic acid) micropellets show similar efficacy and tolerability to mesalazine tablets in patients with ulcerative colitis--results from a randomized-controlled trial.Drug targeting strategies for the treatment of inflammatory bowel disease: a mechanistic update.Characterization of epithelial IL-8 response to inflammatory bowel disease mucosal E. coli and its inhibition by mesalamine.Urinalysis of MMX-mesalazine as a tool to monitor 5-ASA adherence in daily IBD practice.Dissolution of mesalazine modified release tablets under standard and bio-relevant test conditions.Comparison of efficacy of once daily multimatrix mesalazine 2.4 g/day and 4.8 g/day with other 5-aminosalicylic acid preparation in active ulcerative colitis: a randomized, double-blind study.

P2860

Q26777729-F6DFA4EF-8272-46F7-B5A5-98D8E2A120D4 Q27325548-B386A631-9DE0-4CA5-8AE3-3B25B534DE01 Q28260710-58D47271-CD77-428F-92FF-49CC80137561 Q33819512-CA68D67D-C20D-41A0-98FD-4B4CB695CBDC Q33868970-C84F5A0E-B55A-4C24-90B1-7E8AF87B6E03 Q34025054-DA4809A1-301F-45BD-873D-575A55626C87 Q34608415-73D98A58-E1EA-4B98-8414-F6BE8762C47D Q34818798-62A15590-23AB-4AB2-B2E9-3D2B89F2723D Q35654665-021309E8-9F64-4FE8-B1B0-D4CBAEE96FED Q36316765-B9212B8F-ED6B-4CF9-B1D7-49586194583C Q36403491-4F4546BE-3AF5-4EAF-AE62-CE8A71730AE2 Q36555966-193E8AA2-01D6-4CE4-BB3D-42021617CDCA Q36580628-0CE9D8CC-C920-4F4E-AA69-6AC058E3D627 Q37162453-6189B76A-A1FF-44F7-BF76-F356DD421655 Q37236388-E5BA39E1-72A0-42B0-9C60-6E8C4700A841 Q37439929-0BE1C7A8-5C6E-450D-AF91-2501C7E25FA0 Q37850826-334EB6F1-BA70-4991-90EC-A5DA81A7B3A7 Q37854596-072818E2-B852-4828-94D6-F544DA826F5A Q38110619-5FD3F77D-5278-4B4D-A7CB-3BBFF924572C Q38200842-7120FA09-BA2D-4756-8022-353A1B52E2B0 Q38288749-B2D57646-F9CC-4AA9-A049-0A37D79B0131 Q38501680-193A2003-3C3B-4F76-BE2F-51B8DB0D6368 Q38571119-EC018FE6-DDCF-46C4-824A-D19BC8441AA0 Q39401950-7215A42A-3704-4B5F-8EB6-AB781BBBC96A Q40966135-0B1BEB58-460F-4E9D-AFE2-E8B93EA08636 Q42684786-FDA5EB77-23EA-4A45-8567-5E608FFE9D29 Q42945264-9BF04F0B-B3BF-4731-8026-9C284D76123C Q43714774-2FDF1F6A-0772-452F-9FE7-85B2BEB885E6 Q43769282-9BB166AF-B9A8-4F4D-8B7F-8C58307631F8 Q45192026-382B67D8-D9AA-4C31-864F-2FC2FD38591F Q45861878-F07F1962-F792-4FC8-9A13-CD95CD96A5D5 Q46946721-CCDA2307-1F78-4C68-8173-7F781F7A1090 Q48122081-FFAC5764-301A-4D75-966A-00257829122A Q53347908-87B5D927-4E8A-4C0B-8862-BB48058B0D2C Q55036784-B67D1566-0A1A-40B7-A786-F28268385259

P2860

Mucosal 5-aminosalicylic acid concentration inversely correlates with severity of colonic inflammation in patients with ulcerative colitis.

http://www.wikidata.org/entity/Q35361187

description

2000 nî lūn-bûn

@nan

2000 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2000 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2000年の論文

@ja

2000年論文

@yue

2000年論文

@zh-hant

2000年論文

@zh-hk

2000年論文

@zh-mo

2000年論文

@zh-tw

2000年论文

@wuu

name

Mucosal 5-aminosalicylic acid ...... ients with ulcerative colitis.

@ast

Mucosal 5-aminosalicylic acid ...... ients with ulcerative colitis.

@en

type

label

Mucosal 5-aminosalicylic acid ...... ients with ulcerative colitis.

@ast

Mucosal 5-aminosalicylic acid ...... ients with ulcerative colitis.

@en

prefLabel

Mucosal 5-aminosalicylic acid ...... ients with ulcerative colitis.

@ast

Mucosal 5-aminosalicylic acid ...... ients with ulcerative colitis.

@en

P1433

Q35361187-BFBFF9DF-5BAF-4574-86D5-F5C7B982A0C7

P1476

Q35361187-A429A3A6-46A0-4F75-9317-F9AD6B488A56

P2093

Q35361187-0FB00582-39D4-4862-BAFC-598367E464C3

Q35361187-395AC665-EA54-49D8-B359-FCA059F48E06

Q35361187-7B8DEBD0-C302-4C24-A051-08A803FD253A

Q35361187-7F9D28D0-182E-4F9F-9ED7-E43829537D28

Q35361187-994ACCD7-5152-4435-BB9D-1DBDCF355C38

Q35361187-AF1B420C-26E5-4C23-95AC-6645E387E90A

Q35361187-B46C0DDF-88C9-419D-9112-7B3D76EB0AD9

P2860

Q35361187-00141DE1-479D-46BE-B2FE-282DBA105B6C

Q35361187-0665684C-4EE8-4709-8E98-BD47057D85DF

Q35361187-34054C26-4347-4498-8D08-50F3F682C759

Q35361187-3701767D-3818-43B0-9BA3-1FD90DFFEBE0

Q35361187-3C1EC8DC-83A9-434C-A73A-0C8943CA4064

Q35361187-485985D2-4E7A-4017-A3D7-CB25D9797FBA

Q35361187-491BEDAA-14B4-4174-A95F-8D17B3077DA2

Q35361187-544F7498-11CE-4A06-BEF3-C7240315CA90

Q35361187-654808D7-2769-432D-920E-35D813127049

Q35361187-7964014E-FD83-40A2-9E33-4786A83A42A9

P304

Q35361187-B0512F88-DB50-4EE6-AFBC-39D4D50915A7

P31

Q35361187-291C5BE5-A107-4D6C-97B5-CB77EBB4FC54

P356

Q35361187-7E25EBBA-C8DC-4CD2-B7EB-D6A72ED94CC7

P407

Q35361187-E2EE78A7-7198-404B-853C-921D60203C16

P433

Q35361187-86CD9709-BA7E-4A54-B44D-3E2930F79137

P478

Q35361187-1C7E7CF7-422B-4AEF-A5E6-9541470798F1

P577

Q35361187-7C928EB3-11D4-4E63-9A15-BD017B871404

P5875

Q35361187-B7C0FAF2-AAE1-41D8-B7A1-DE032018FEC6

P698

Q35361187-7F489ED9-88E7-433F-B93C-18C5A5F64572

P921

Q35361187-64B3F84A-1069-49E9-AC6D-A0E09DCE80CF

P932

Q35361187-970B828F-9CF1-48AC-AD7A-8C61373F426D

P356

P1433

P1476

Mucosal 5-aminosalicylic acid ...... ients with ulcerative colitis.

@en

P2093

Caprilli R

http://www.w3.org/2001/XMLSchema#string

Frieri G

http://www.w3.org/2001/XMLSchema#string

Giacomelli R

http://www.w3.org/2001/XMLSchema#string

Palumbo G

http://www.w3.org/2001/XMLSchema#string

Pantaleoni G

http://www.w3.org/2001/XMLSchema#string

Passacantando A

http://www.w3.org/2001/XMLSchema#string

Pimpo M

http://www.w3.org/2001/XMLSchema#string

P2860

Inflammatory bowel disease

Inhibition of leucocyte adhesion molecule upregulation by tumor necrosis factor alpha: a novel mechanism of action of sulphasalazine.

Mesalamine blocks tumor necrosis factor growth inhibition and nuclear factor kappaB activation in mouse colonocytes.

Oral delayed-release mesalazine: a review of its use in ulcerative colitis and Crohn's disease.

Increased concentrations of interleukin 1 beta, interleukin-2, and soluble interleukin-2 receptors in endoscopical mucosal biopsy specimens with active inflammatory bowel disease

Optimum dose of olsalazine for maintaining remission in ulcerative colitis.

Disposition of 5-aminosalicylic acid by olsalazine and three mesalazine preparations in patients with ulcerative colitis: comparison of intraluminal colonic concentrations, serum values, and urinary excretion

Optimum dosage of 5-aminosalicylic acid as rectal enemas in patients with active ulcerative colitis

5-Aminosalicylic acid is a potent inhibitor of interleukin 1 beta production in organ culture of colonic biopsy specimens from patients with inflammatory bowel disease

Concentrations of 5-ASA and Ac-5-ASA in human ileocolonic biopsy homogenates after oral 5-ASA preparations.

P304

410-414

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/GUT.47.3.410

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

47

http://www.w3.org/2001/XMLSchema#string

P577

2000-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

277517212

http://www.w3.org/2001/XMLSchema#string

P698

10940280

http://www.w3.org/2001/XMLSchema#string

P921

P932

1728031

http://www.w3.org/2001/XMLSchema#string